Jacob Asset Management of New York LLC Has $208,000 Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Jacob Asset Management of New York LLC raised its position in CareDx, Inc (NASDAQ:CDNA) by 9.2% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 24,465 shares of the company’s stock after purchasing an additional 2,054 shares during the period. Jacob Asset Management of New York LLC’s holdings in CareDx were worth $208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in CareDx by 9.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 256,271 shares of the company’s stock valued at $2,179,000 after buying an additional 21,955 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in CareDx by 26.8% in the second quarter. Russell Investments Group Ltd. now owns 64,072 shares of the company’s stock valued at $545,000 after buying an additional 13,536 shares in the last quarter. Cetera Advisor Networks LLC boosted its stake in CareDx by 7.3% in the second quarter. Cetera Advisor Networks LLC now owns 38,708 shares of the company’s stock valued at $329,000 after buying an additional 2,625 shares in the last quarter. Rhumbline Advisers boosted its stake in CareDx by 32.5% in the second quarter. Rhumbline Advisers now owns 90,656 shares of the company’s stock valued at $771,000 after buying an additional 22,240 shares in the last quarter. Finally, Gagnon Advisors LLC boosted its stake in CareDx by 5.5% in the second quarter. Gagnon Advisors LLC now owns 554,851 shares of the company’s stock valued at $4,716,000 after buying an additional 28,763 shares in the last quarter.

CareDx Trading Up 4.4 %

CDNA stock traded up $0.40 during mid-day trading on Friday, reaching $9.53. The company’s stock had a trading volume of 1,373,193 shares, compared to its average volume of 1,052,066. The company has a market cap of $515.55 million, a price-to-earnings ratio of -5.71 and a beta of 1.05. The business’s 50 day moving average price is $6.82 and its 200 day moving average price is $8.23. CareDx, Inc has a 12 month low of $4.80 and a 12 month high of $18.04.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, November 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $67.19 million during the quarter, compared to the consensus estimate of $53.14 million. CareDx had a negative return on equity of 21.94% and a negative net margin of 30.46%. The company’s revenue for the quarter was down 15.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. As a group, equities analysts expect that CareDx, Inc will post -2.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other CareDx news, insider Reginald Seeto sold 2,819 shares of CareDx stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $9.49, for a total value of $26,752.31. Following the completion of the sale, the insider now directly owns 481,982 shares in the company, valued at $4,574,009.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating on shares of CareDx in a research note on Wednesday, August 9th. StockNews.com began coverage on CareDx in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Stephens upgraded CareDx from an “equal weight” rating to an “overweight” rating and set a $10.00 target price for the company in a research report on Thursday, November 9th. Finally, Raymond James upgraded CareDx from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Tuesday, August 15th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, CareDx currently has an average rating of “Hold” and a consensus target price of $13.80.

CareDx Profile

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.